# Prolium Bioscience

> Prolium Bioscience is a New York-based, clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager designed to deplete disease-driving B cells as an off-the-shelf therapy for severe autoimmune diseases, starting with systemic sclerosis and lupus. Founded in 2025 and backed by RTW Investments, the company in-licensed global non-oncology and ex-Asia oncology rights to the antibody from China's InnoCare Pharma and KeyMed Biosciences, and launched publicly in March 2026 with a $50 million Series A alongside first-patient dosing.

- **Founded:** 2025
- **Headquarters:** New York, New York, United States
- **Founders:** Scott Requadt (Founder & Chief Executive Officer), RTW Investments, LP (Founding Investor / Company Builder)
- **Team size:** ~8 employees
- **Products:** PRO-203 (ICP-B02)
- **Notable:** Launched publicly in March 2026 with a $50 million Series A led by founding investor RTW Investments., Secured global non-oncology and ex-Asia oncology rights to a clinical-stage CD20xCD3 bispecific in a deal worth up to $520M ($17.5M upfront/near-term, up to $502.5M in milestones plus royalties and equity)., Dosed first healthy volunteers in a single ascending dose study of PRO-203.

## Products & services

- **PRO-203 (ICP-B02)** — A bispecific CD20xCD3 T-cell engager antibody that simultaneously binds CD20 on B cells and CD3 on T cells, forming an immunological synapse that redirects T cells to eliminate disease-driving B cells via T-cell dependent cellular cytotoxicity. Administered subcutaneously and positioned as an off-the-shelf alternative to CAR-T, without patient-specific manufacturing. Being developed first for systemic sclerosis and lupus.

## Achievements

- Launched publicly in March 2026 with a $50 million Series A led by founding investor RTW Investments.
- Secured global non-oncology and ex-Asia oncology rights to a clinical-stage CD20xCD3 bispecific in a deal worth up to $520M ($17.5M upfront/near-term, up to $502.5M in milestones plus royalties and equity).
- Dosed first healthy volunteers in a single ascending dose study of PRO-203.
- Treated five refractory systemic lupus erythematosus / lupus nephritis patients in an investigator-initiated study, completing 26-week follow-up.
- Dosed the first patient in a multinational Phase 1/2 systemic sclerosis study spanning 20+ sites in at least five countries (June 2026).

## Latest updates

- **2026-06** — Announced first patient dosed in its multinational Phase 1/2 study of PRO-203 in systemic sclerosis (up to 24 patients, 20+ sites, 5+ countries) and last-patient-last-visit in the investigator-led refractory lupus nephritis study.
- **2026-03** — Emerged from stealth with a $50M Series A and disclosed first patients dosed with PRO-203 across healthy-volunteer and lupus studies.
- **2025-01** — InnoCare Pharma and KeyMed Biosciences announced the exclusive license agreement granting Prolium rights to the CD20xCD3 bispecific antibody ICP-B02 (PRO-203).

## Links

- Website: https://proliumbio.com
- LinkedIn: http://www.linkedin.com/company/prolium-bio

---

Profile page: https://yespress.io/prolium-bioscience
Published by YesPress — https://yespress.io
Last updated: 2026-07-18